Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of clindamycin-based exposure strategies in experimental mature staphylococcal biofilms.
Microbiol Spectr
January 2025
Center for Infectious Diseases, Lab of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
Unlabelled: Due to increasing antimicrobial resistance and side effects caused by current standard antimicrobial regimens used for treatment of prosthetic joint infection (PJI), alternative options are urgently needed. We aimed to investigate the effect of clindamycin in different exposure strategies against in an mature biofilm model. In short, 7-day biofilms were generated on polystyrene plates and titanium-aluminum-vanadium discs using a clinical PJI isolate.
View Article and Find Full Text PDFA Unique Prodrug Targeting the Prostate-Specific Membrane Antigen for the Delivery of Monomethyl Auristatin E.
Bioconjug Chem
January 2025
Department of Chemistry, Washington State University, Pullman, Washington 99164, United States.
Monomethyl auristatin E (MMAE) is a promising treatment option for patients diagnosed with prostate cancer (PCa); however, toxicities prevent MMAE from being administered as free drug. No MMAE-based treatment is currently marketed for PCa. Herein, we describe a small-molecule-drug conjugate, CTT2274, for the selective delivery of MMAE.
View Article and Find Full Text PDFAssessment of a New CT Detector and Filtration Technology: Part 1 - X-ray Beam Characterization and Radiation Dosimetry.
J Comput Assist Tomogr
January 2025
Department of Radiology, College of Medicine, University of Florida, Gainesville, FL.
Purpose: This study evaluated beam quality and radiation dosimetry of a CT scanner equipped with a novel detector and filtration technology called PureVision Optics (PVO). PVO features miniaturized electronics, a detector cut with microblade technology, and increased filtration in order to increase x-ray detection and reduce image noise.
Methods: We assessed the performance of two similar 320-detector CT scanners: one equipped with PVO and one without.
First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.
Clin Kidney J
January 2025
Department of General Internal Medicine and Nephrology, Robert Bosch Hospital Stuttgart, Stuttgart, Germany.
Background: Sparsentan, a dual-acting antagonist for both the angiotensin II receptor type 1 and the endothelin receptor type A, has emerged as a promising therapeutic agent for the treatment of IgA nephropathy (IgAN). Following the publication of the PROTECT trial, sparsentan recently received approval for the treatment of IgAN in Europe. However, it remains uncertain whether an additive effect can be observed in the context of existing treatment with sodium-glucose co-transporter 2 (SGLT2) inhibitors, given that the PROTECT study did not investigate this dual therapy approach.
View Article and Find Full Text PDFDurable suppression of seizures in a preclinical model of KCNT1 genetic epilepsy with divalent small interfering RNA.
Epilepsia
January 2025
Atalanta Therapeutics, Boston, Massachusetts, USA.
Objective: Gain-of-function variants in the KCNT1 gene, which encodes a sodium-activated potassium ion channel, drive severe early onset developmental epileptic encephalopathies including epilepsy of infancy with migrating focal seizures and sleep-related hypermotor epilepsy. No therapy provides more than sporadic or incremental improvement. Here, we report suppression of seizures in a genetic mouse model of KCNT1 epilepsy by reducing Kcnt1 transcript with divalent small interfering RNA (siRNA), an emerging variant of oligonucleotide technology developed for the central nervous system.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!